Sorafenib
- Generic Name
- Sorafenib
- Brand Names
- Nexavar, Sorafenib Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C21H16ClF3N4O3
- CAS Number
- 284461-73-0
- Unique Ingredient Identifier
- 9ZOQ3TZI87
- Background
Sorafenib is a bi-aryl urea and an oral multikinase inhibitor. It targets cell surface tyrosine kinase receptors and downstream intracellular kinases that are implicated in tumour cell proliferation and tumour angiogenesis. First approved by the FDA and European Commission in 2007 for the treatment of hepatocellular carcinoma, sorafenib is also indicated to ...
- Indication
Sorafenib is indicated for the treatment of unresectable hepatocellular carcinoma and advanced renal cell carcinoma.
In the US, it is also indicated for the treatment of patients with locally recurrent or metastatic, progressive, differentiated thyroid carcinoma that is refractory to radioactive iodine treatment.
- Associated Conditions
- Advanced Renal Cell Carcinoma, Angiosarcoma, Gastrointestinal Stromal Tumor (GIST), Leiomyosarcoma (LMS), Unresectable Hepatocellular Carcinoma (HCC), Progressive, locally recurrent radioactive iodine-refractory Differentiated Thyroid Carcinoma (DTC), Progressive, metastatic radioactive iodine-refractory Differentiated Thyroid Carcinoma (DTC)
- Associated Therapies
- -
Sorafenib and Bavituximab Plus SBRT in Unresectable Hepatocellular Carcinoma
- Locations
- 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
Study of Safety and Tolerability of PDR001 in Combination With Sorafenib and to Identify the Maximum Tolerated Dose and/or Phase 2 Dose for This Combination in Advanced Hepatocellular Patients
- First Posted Date
- 2016-12-09
- Last Posted Date
- 2020-12-19
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 20
- Registration Number
- NCT02988440
- Locations
- 🇺🇸
Karmanos Cancer Institute, Detroit, Michigan, United States
🇨🇳Novartis Investigative Site, Taipei, Taiwan
Circulating Tumor Cells and Tumor DNA in HCC and NET
- First Posted Date
- 2016-11-25
- Last Posted Date
- 2021-04-28
- Lead Sponsor
- University of Aarhus
- Target Recruit Count
- 167
- Registration Number
- NCT02973204
- Locations
- 🇩🇰
Department of Hepatology and Gastroenterology, Aarhus, Aarhus C, Denmark
Sorafenib Versus Best Supportive Care in Egyptian Hepatocellular Carcinoma Patients.
- First Posted Date
- 2016-11-23
- Last Posted Date
- 2018-06-27
- Lead Sponsor
- Ain Shams University
- Target Recruit Count
- 55
- Registration Number
- NCT02971696
- Locations
- 🇪🇬
Ain Shams University Hospital, Cairo, Egypt
🇪🇬El Kahraba Hosital, Cairo, N/A = Not Applicable, Egypt
🇪🇬Nasser Institute, Cairo, Egypt
Preventive Effect of Celecoxib on Sorafenib-related Hand Foot Syndrome, a Single Center, Randomized Controlled Clinical Trail
- First Posted Date
- 2016-11-11
- Last Posted Date
- 2019-09-10
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 116
- Registration Number
- NCT02961998
Sorafenib Treatment in Patients With Hepatocellular Carcinoma With Microvascular Invasion After Radical Resection
- First Posted Date
- 2016-08-15
- Last Posted Date
- 2020-02-11
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 154
- Registration Number
- NCT02867280
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
Molecularly Target Therapy With GEMOX in Advanced or Recurrent Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma
- First Posted Date
- 2016-07-19
- Last Posted Date
- 2018-05-07
- Lead Sponsor
- Shanghai Jiao Tong University School of Medicine
- Target Recruit Count
- 152
- Registration Number
- NCT02836847
- Locations
- 🇨🇳
Xinhua Hospital, Shanghai, Shanghai, China
TACE vs TACE+SBRT for Unresectable Hepatocellular Cancer
- Conditions
- Interventions
- First Posted Date
- 2016-06-09
- Last Posted Date
- 2022-04-27
- Lead Sponsor
- Tata Memorial Hospital
- Target Recruit Count
- 67
- Registration Number
- NCT02794337
- Locations
- 🇮🇳
Advanced Centre for Treatment, Research and Education in Cancer, Tata Memorial Centre, Navi Mumbai, Maharashtra, India
🇮🇳Advanced Centre of Treatment Research and Education In Cancer,Tata Memorial Centre, Navi Mumbai, Maharashtra, India
Sorafenib Alone Versus Sorafenib Combined With HAIC for Advanced HCC
- Conditions
- Interventions
- First Posted Date
- 2016-05-17
- Last Posted Date
- 2019-12-05
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 247
- Registration Number
- NCT02774187
- Locations
- 🇨🇳
The Kaiping Center's Hospital, Kaiping, Guangdong, China
🇨🇳Cancer Center Sun Yat-sen University, Guangzhou, Guangdong, China
🇨🇳Guangzhou Twelfth People 's Hospita, Guangzhou, Guangdong, China
Sorafenib Combined With Aspirin to Prevent the Recurrence in High-risk Patients With Hepatocellular Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2016-04-22
- Last Posted Date
- 2019-02-15
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 52
- Registration Number
- NCT02748304
- Locations
- 🇨🇳
Huashan hospital, Shanghai, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.